Spyre Therapeutics, Inc. · NASDAQ:SYRE
Turtle Cameron sold 15,000 Spyre Therapeutics, Inc. shares (Form 4)
Traded Aug 3, 2026 · Filed Aug 5, 2026
On Aug 3, 2026, Turtle Cameron (Director, Chief Executive Officer) sold 15,000 Spyre Therapeutics, Inc. shares at an average US$95.51 for US$1.43M under a trading plan, leaving 567,540 shares. Filed Aug 5, 2026 (Form 4).
- Sold
- 15,000 shares
- Price
- US$95.51 average (US$93.97 to US$97.46)
- Value
- US$1.43M
- Holding after
- 567,540 shares
- Trading plan
- Yes (Made under a plan set in advance)
- Role
- Director, Chief Executive Officer
The filing in full
| Date | Security | Transaction | Shares | Price | Holding after | Ownership |
|---|---|---|---|---|---|---|
| Aug 3, 2026 | Common Stock | Sale | 800 | US$93.97 | 581,740 | Direct |
| Aug 3, 2026 | Common Stock | Sale | 7,157 | US$95.10 | 574,583 | Direct |
| Aug 3, 2026 | Common Stock | Sale | 5,635 | US$95.93 | 568,948 | Direct |
| Aug 3, 2026 | Common Stock | Sale | 1,392 | US$96.82 | 567,556 | Direct |
| Aug 3, 2026 | Common Stock | Sale | 16 | US$97.46 | 567,540 | Direct |
Source
Related
- Spyre Therapeutics, Inc.
- Turtle Cameron
- Spyre Therapeutics, Inc. shareholders
- Form 4 · Turtle Cameron · Oct 2, 2026
- Form 4 · Turtle Cameron · Sep 3, 2026
- Form 4 · Turtle Cameron · Jul 2, 2026
- Form 4 · Turtle Cameron · Jun 3, 2026
- Form 4 · Turtle Cameron · May 1, 2026
- Schedule 13D/A · Harwin Peter Evan · Oct 9, 2026
- Form 4 · Burrows Scott L · Oct 2, 2026
- Form 4 · King-Jones Heidy · Oct 2, 2026
- Schedule 13G · Paradigm Biocapital Advisors LP · Oct 1, 2026
- Form 4 · King-Jones Heidy · Sep 3, 2026